1 Abstract
Background Ovarian cancer is the leading cause of gynecological cancer deaths due to late diagnosis and high recurrence rates. While histopathological analysis is the gold standard for diagnosis, artificial intelligence (AI) models have shown promise in accurately classifying ovarian cancer subtypes from his-topathology images. Herein, we developed an AI pipeline for automated identification of epithelial ovar-ian cancer (EOC) subtypes based on histopathology images and evaluated its performance compared to the pathologists’ diagnosis.
Methods A dataset of over 2 million image tiles from 82 whole slide images (WSIs) of the major EOC subtypes (clear cell, endometrioid, mucinous, serous) was curated from public and institutional sources. A convolutional neural network (ResNet50) was used to extract features which were then input to 2 classifiers (CNN, and LightGBM) to predict the cancer subtype.
Results Both AI classifiers achieved patch-level accuracy (97-98%) on the test set. Furthermore, adding a class-weighted cross-entropy loss function to the pipeline showed better discriminative performance between the subtypes.
Conclusion AI models trained on histopathology image data can accurately classify EOC subtypes, potentially assisting pathologists and reducing subjectivity in ovarian cancer diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB of Imam AbdulRahman bin Faisal University gave ethical approval for this work: IRB-UGS-2023-01-410, approved on 22/10/2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors